Bavarian Nordic says Phase 2 trial supports EU approval of IMVANEX mpox vaccine in children 2-11
Reuters2026/08/07 06:00- Bavarian Nordic secured European Commission clearance to expand IMVANEX use to children aged 2 to under 12.
- The decision relied on results already generated in a Phase 2 trial comparing children with adults.
- The study showed children produced an immune response comparable to adults with a similar safety profile.
- The label expansion broadens EU access to the company’s non-replicating MVA-BN vaccine for mpox and smallpox preparedness.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Artiva Biotherapeutics CMO Subhashis Banerjee disposes of 8,222 shares for $98,730.32
Cang (CANG.US) Q2 total revenue fell about 50% quarter-on-quarter; mined 656 bitcoins
Cango announced its financial results for the second quarter of 2026.
Trump boasts "US economy can grow by 20%", says the Federal Reserve should not raise rates because of this
US President Trump, while announcing an agreement in the Oval Office aimed at lowering prescription drug prices, stated that the US economy could grow at a rate of 14%, 15%, 16%, or even 20%, emphasizing that such rapid growth should not prompt the Federal Reserve to raise interest rates.
Zcash Price Targets $1800 as Privacy Demand Fuels Rally
Crypto prices
More
